Definium Therapeutics (DFTX) Total Non-Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has reported Total Non-Current Liabilities for 7 consecutive years, with $121.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 251.54% year-over-year to $121.9 million; the TTM figure through Mar 2026 stood at $121.9 million (up 251.54% YoY), while the FY2025 annual figure was $107.3 million, up 201.81% from the prior year.
• Total Non-Current Liabilities improved to $121.9 million in Q1 2026 per DFTX's latest filing, from $107.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $121.9 million in Q1 2026 and bottomed at $7.9 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $51.7 million across 5 years, with a median of $35.5 million in 2024.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 346.21% — and 2025, when it sank 56.36%.
• Definium Therapeutics' Total Non-Current Liabilities stood at $17.9 million in 2022, then jumped by 159.19% to $46.4 million in 2023, then decreased by 23.35% to $35.5 million in 2024, then surged by 201.81% to $107.3 million in 2025, then gained by 13.62% to $121.9 million in 2026.
• Business Quant data shows DFTX's Total Non-Current Liabilities at $121.9 million in Q1 2026, $107.3 million in Q4 2025, and $105.8 million in Q3 2025.